Fusion Genes Diagnosis Uses Targeted RNA Sequencing
By LabMedica International staff writers Posted on 10 Apr 2019 |
Image: The HiSeq 2500 sequencing system offers unprecedented output (Photo courtesy of the University of Delaware).
Chromosomal rearrangements that juxtapose two different genes together can form a fusion gene. Fusion genes play a causal role in tumorigenesis, accounting for ~20% of human cancer morbidity. However, the prevalence of fusion genes varies widely across different cancers, and many fusion genes are specific to certain cancer sub-types.
Precise fusion gene diagnosis can also inform subsequent therapeutic treatment, with several drugs having been successfully developed to inhibit fusion genes. Fusion gene diagnosis can also predict prognosis, patient survival and treatment response. Fluorescence in situ hybridization (FISH) and quantitative real-time polymerase chain reaction (RT-PCR) methods have been predominantly used for fusion gene diagnosis.
Scientists at the Garvan Institute of Medical Research (Sydney, Australia) and their colleagues established that fusion gene detection with targeted RNAseq is both sensitive and quantitative by optimizing laboratory and bioinformatic variables using spike-in standards and cell lines. Next, they analyzed a clinical patient cohort and improve the overall fusion gene diagnostic rate from 63% with conventional approaches to 76% with targeted RNAseq while demonstrating high concordance for patient samples with previous diagnoses. All libraries were sequenced on an Illumina HiSeq 2500 v4.0 platform.
The team tested their new method using clinical cancer patient samples, including samples from the Molecular Screening and Therapeutics (MoST) clinical trials, and discovered that their RNA analysis not only more accurately detected fusion genes previously identified with FISH analyses, but that it identified 20% more fusion genes that the FISH analyses missed.
Erin Heyer, PhD, the first author of the study, said, “The approach we've taken in our study is to wipe away the information about where the cancer is found, we take a broad view and just look at genes that are known to be involved in fusions across all cancer subtypes.” The study was published on March 27, 2019, in the journal Nature Communications.
Related Links:
Garvan Institute of Medical Research
Precise fusion gene diagnosis can also inform subsequent therapeutic treatment, with several drugs having been successfully developed to inhibit fusion genes. Fusion gene diagnosis can also predict prognosis, patient survival and treatment response. Fluorescence in situ hybridization (FISH) and quantitative real-time polymerase chain reaction (RT-PCR) methods have been predominantly used for fusion gene diagnosis.
Scientists at the Garvan Institute of Medical Research (Sydney, Australia) and their colleagues established that fusion gene detection with targeted RNAseq is both sensitive and quantitative by optimizing laboratory and bioinformatic variables using spike-in standards and cell lines. Next, they analyzed a clinical patient cohort and improve the overall fusion gene diagnostic rate from 63% with conventional approaches to 76% with targeted RNAseq while demonstrating high concordance for patient samples with previous diagnoses. All libraries were sequenced on an Illumina HiSeq 2500 v4.0 platform.
The team tested their new method using clinical cancer patient samples, including samples from the Molecular Screening and Therapeutics (MoST) clinical trials, and discovered that their RNA analysis not only more accurately detected fusion genes previously identified with FISH analyses, but that it identified 20% more fusion genes that the FISH analyses missed.
Erin Heyer, PhD, the first author of the study, said, “The approach we've taken in our study is to wipe away the information about where the cancer is found, we take a broad view and just look at genes that are known to be involved in fusions across all cancer subtypes.” The study was published on March 27, 2019, in the journal Nature Communications.
Related Links:
Garvan Institute of Medical Research
Latest Molecular Diagnostics News
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer